DOI: 10.12890/2026_007318
VEXAS syndrome: a multisystem challenge with sweet syndrome and myelodysplastic syndrome
Authors
miriamlaf97@gmail.com
Keywords
Sweet syndrome (SS), myelodysplastic syndrome (MDS), VEXAS syndrome, UBA1 mutationAbstract
Introduction: VEXAS (vacuoles, E1 enzyme, x-linked, autoinflammatory, somatic) syndrome, is a recently described autoinflammatory condition caused by UBA1 gene mutations. It can present with both sweet syndrome (SS) and myelodysplastic syndrome (MDS). SS, or acute febrile neutrophilic dermatosis, is an inflammatory disorder characterised by fever, neutrophilia and painful erythematous plaques. MDS is a clonal haematopoietic stem cell disorder.
Case description: We present a case of a 43-year-old Arab male with a history of MDS. He presented with painful, non-pruritic, non-haemorrhagic skin lesions. The patient also reported having fever and chills, partially relieved by antipyretics. Bone marrow aspiration was done and revealed a ‘dry tap’ which was inadequate for evaluation. Immunophenotyping of bone marrow biopsy was consistent with MDS. A skin biopsy of the lesions was performed and confirmed sweet syndrome. The patient was treated with methylprednisolone 500 mg daily for five days, with a significant improvement in clinical symptoms. After stabilisation, treatment for MDS was started with 200 mg IV azacitidine daily for seven days.
Conclusion: Given the patient’s age, gender, MDS diagnosis and atypical presentation of sweet syndrome, VEXAS syndrome is a strong possibility. Further investigation, including genetic testing for a UBA1 mutation, is warranted. A diagnosis of VEXAS syndrome would significantly impact long-term management and prognosis, as it was determined to be important in reducing the recurrence rate of sweet syndrome.
References
- Nofal A, Abdelmaksoud A, Amer H, Nofal E, Yosef A, Gharib K, et al. Sweet’s syndrome: diagnostic criteria revisited. J Dtsch Dermatol Ges 2017;15:1081-1088. doi: 10.1111/ddg.13350
- Cohen PR. Sweet’s syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007;2:34. doi: 10.1186/1750-1172-2-34
- Santos ML, Ferreira I, Embaló U, Alves G, Cotter J. Sweet’s Syndrome: A Case of Fever and Painful Erythematous Nodules Following a Viral-Like Illness. Cureus 2026;18:e100701. doi: 10.7759/cureus.100701
- Joshi TP, Friske SK, Hsiou DA, Duvic M. New Practical Aspects of Sweet Syndrome. Am J Clin Dermatol 2022;23:301-318. doi: 10.1007/s40257-022-00673-4
- von den Driesch P. Sweet’s syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol 1994;31:535-556; quiz 557-560. doi: 10.1016/s0190-9622(94)70215-2
- Obiorah IE, Patel BA, Groarke EM, Wang W, Trick M, Ombrello AK, et al. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv 2021;5:3203-3215. doi: 10.1182/bloodadvances.2021004976
- Loeza-Uribe MP, Hinojosa-Azaola A, Sánchez-Hernández BE, Crispín JC, Apodaca-Chávez E, Ferrada MA, et al. VEXAS syndrome: Clinical manifestations, diagnosis, and treatment. Reumatol Clin (Engl Ed) 2024;20:47-56. doi: 10.1016/j.reumae.2023.12.004
- Boyadzhieva Z, Ruffer N, Kötter I, Krusche M. How to treat VEXAS syndrome: a systematic review on effectiveness and safety of current treatment strategies. Rheumatology (Oxford) 2023;62:3518-3525. doi: 10.1093/rheumatology/kead240
- Wolff L, Caratsch L, Zhao LP, Blum S, Comte D. Understanding Myelodysplasia and Inflammation Through the Lense of VEXAS Syndrome: A Review. Cells 2024;13:1890. doi: 10.3390/cells13221890
- Kucharz EJ. VEXAS syndrome: a newly discovered systemic rheumatic disorder. Reumatologia 2023;61:123-129. doi: 10.5114/reum/163090
